BiotechTube

Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + Steroids

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Disorder Related to Cardiac Transplantation

Conditions

Disorder Related to Cardiac Transplantation

Trial Timeline

Dec 1, 2005 → Feb 1, 2010

NCT ID
NCT00377962

About Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + Steroids

Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + Steroids is a approved stage product being developed by Novartis for Disorder Related to Cardiac Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00377962. Target conditions include Disorder Related to Cardiac Transplantation.

What happened to similar drugs?

20 of 20 similar drugs in Disorder Related to Cardiac Transplantation were approved

Approved (20) Terminated (2) Active (0)
✅Olanzapine + PlaceboEli LillyApproved
✅atomoxetineEli LillyApproved
✅AtomoxetineEli LillyApproved
✅Duloxetine (Cymbalta)Eli LillyApproved
✅Atomoxetine HydrochlorideEli LillyApproved
✅AtomoxetineEli LillyApproved
✅Atomoxetine hydrochloride + PlaceboEli LillyApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00377962ApprovedCompleted

Competing Products

20 competing products in Disorder Related to Cardiac Transplantation

See all competitors
ProductCompanyStageHype Score
Duloxetine + venlafaxine + placeboEli LillyPhase 3
40
Ketamine + PlaceboRoivant SciencesPhase 1
26
duloxetineEli LillyPre-clinical
26
SUBLOCADEIndivior PLCPhase 3
29
SUBLOCADEIndivior PLCPhase 3
29
TSHA-101Taysha Gene TherapiesPhase 1/2
30
OlanzapineEli LillyPhase 3
32
Valproate + Lithium + Risperidone + OlanzapineEli LillyPhase 3
40
Olanzapine + PlaceboEli LillyApproved
43
Duloxetine HydrochlorideEli LillyPre-clinical
26
LY2216684Eli LillyPhase 1
29
ACT-541468 5 mg + ACT-541468 10 mg + ACT-541468 25 mg + Zolpidem + Placebo 1 + Placebo 2IdorsiaPhase 2
29
LY2216684Eli LillyPhase 1
29
atomoxetineEli LillyApproved
39
Atomoxetine + PlaceboEli LillyPhase 2/3
38
LY2422347 + placeboEli LillyPhase 2
35
Low Dose REN001 + High Dose REN001OnKure TherapeuticsPhase 1
19
AtomoxetineEli LillyApproved
35
DuloxetineEli LillyPhase 3
40
Duloxetine (Cymbalta)Eli LillyApproved
43